Updated Findings Show Olaparib Prolongs OS in Men with mCRPC
September 20th 2020Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.
Read More
Frontline Nivolumab/Ipilimumab Combo with Limited Chemo Improves OS in NSCLC
May 30th 2020Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.
Read More
Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC
May 29th 2020Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.
Read More
Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer
May 13th 2020Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.
Read More
Maintenance Therapy with Olaparib Extends Survival in Relapsed, BRCA+ Ovarian Cancer
May 13th 2020Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.
Read More
All Stakeholders Are Responsible for Genetic Testing
March 7th 2020Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.
Read More
T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer
December 11th 2019Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.
Read More
Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL
June 4th 2019The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.
Read More
Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer
June 1st 2019Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Read More
Individualized Dosing Reduces Niraparib-Related TEAEs in Ovarian Cancer Maintenance
March 17th 2019Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.
Read More
Repeat Use of PARP Inhibitors Could Be Effective Strategy in Ovarian Cancer
March 17th 2019Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.
Read More
Maintenance Niraparib Extends PFS Without Symptoms, Toxicities in Recurrent Ovarian Cancer
March 17th 2019Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.
Read More
Awareness Critical for Identifying irAEs Early in Breast Cancer
March 10th 2019With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.
Read More
Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups
March 9th 2019The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.
Read More
Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers
February 28th 2019A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.
Read More
Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC
February 12th 2019African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.
Read More
FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC
December 21st 2018The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.
Read More